Compare Innodata Inc (INOD) vs 10X Genomics Inc (TXG) Price & Performance

INOD is trading at $61.20, down 3.49% today, showing bearish technical signals despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters with Q1 2026 EPS of $0.42 versus $0.13 expected. Revenue growth accelerated from $252M in 2025 to $317M in 2026, while net profit margins improved from 12.78% to 14.65%. Recent developments include the opening of a motion-capture AI lab and board appointments strengthening cybersecurity expertise.

The stock presents a growth opportunity with strong AI data engineering positioning and expanding margins, but faces headwinds from premium valuation (P/E 47.43) and technical weakness. Key risks include customer concentration and competitive pressures in the AI services sector. Analyst consensus remains bullish with 4 buy ratings versus 2 holds, suggesting potential upside if execution continues.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.